UNSPSC 51432105: Guanfacine

This classification denotes an antihypertensive agent and alpha-adrenergic agonist with the molecular formula C9H9Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30OMY4G3MK, chemically known as n-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide but generally known as guanfacine, which bears US NIH Compound Identifier 3519. European Medicines Agency schedules Guanfacine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07985MIG.

UNSPSC 51432105 Guanfacine is a Commodity code covering individual pharmaceutical products procured by state and local governments for emergency medical services, pharmacy benefit programs, and health agency operations. State and local buyers under this code source medications through direct competitive bids, cooperative purchasing arrangements, and exploratory information requests from vendors positioned to supply through authorized wholesaler networks or direct-to-manufacturer channels. The work solicited ranges from small, discrete medication purchases for emergency responders to large-scale multi-state cooperative agreements covering entire drug categories with flexible pricing models, volume commitments, compliance certifications (cGMP, DSCSA, FDA), and performance penalties for non-compliance. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple state and local jurisdictions.

Recent activity spans Florida, Minnesota (serving multiple states including Oregon), and Texas. The City of Tampa Fire Rescue issued an IFB (Bid No. 26-P-00188, due April 8, 2026) for Advanced Life Support Medications including epinephrine, adenosine, labetalol, and diltiazem, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers with contract effectiveness July 1, 2026, and a two-year initial term with optional extensions. The Texas Health and Human Services Commission issued an RFI (HHS0017013, closed April 3, 2026) to gather vendor capabilities and market intelligence on direct-to-manufacturer prescription programs, signaling potential future formal solicitations as the state develops its Therapeutic Pharmacy Initiative.